Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSD1235 in Atrial Fibrillation or Atrial Flutter
NCT00115791Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Vernakalant with Placebo (2 arms). Primary endpoint: Conversion of atrial fibrillation or atrial flutter to sinus rhythm. Started Jun 2004; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00115791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115791.